Caliway Secures China Clinical Clearance for CBL-514
New Taipei City, Taiwan, November 19, 2026 Caliway Biopharmaceuticals Co., Ltd. has announced that its investigational injectable drug candidate...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 Clinical Trial Phase 3 trial Precision Medicine Precision Oncology rare disease solid tumors targeted therapy
New Taipei City, Taiwan, November 19, 2026 Caliway Biopharmaceuticals Co., Ltd. has announced that its investigational injectable drug candidate...
New Taipei City, Taiwan, September 22, 2026 Caliway Biopharmaceuticals has announced positive final results from its randomized, single-blind, placebo-controlled...
June 10, 2026 – Taipei, Taiwan Caliway Biopharmaceuticals announced new preclinical data demonstrating the potential of its proprietary fat-reduction...
NEW TAIPEI CITY, Taiwan, May 18, 2026 Caliway Biopharmaceuticals unveiled new preclinical findings at the European Congress on Obesity...
